Tracey Roizman

A retrospective study found that the total healthcare costs in menopausal women treated for vasomotor symptoms were moderately greater compared to those of untreated menopausal women  Vasomotor symptoms are the predominant symptoms among menopausal women; however, these mostly remain untreated. While hormone therapy is the commonly administered treatment option, the lack of compliance with this...

A retrospective study reports that dietary supplementation with myo-inositol, cocoa polyphenols, and soy isoflavones positively affects the metabolic profile and vasomotor symptoms of menopausal women with metabolic syndrome. Hormonal changes occurring physiologically during the menopausal transition are associated with an increased risk for metabolic disturbances and vasomotor symptoms. One of the complications of these changes...

While the presence of vasomotor symptoms is associated with low bone mineral density among postmenopausal women, it is not related to an increase in the risk of fractures, according to the findings of a new literature review. Vasomotor symptoms affect the quality of life of postmenopausal women. Other health complications associated with the menopausal transition...

Compared to the general population, the incidence of anxiety in perimenopausal women was relatively greater and was associated with impaired quality of life in perimenopausal women in a questionnaire-based study. Vasomotor symptoms in perimenopausal women have a significant effect on the quality of life of perimenopausal women. In addition to these symptoms, perimenopausal women also...

A screening of the differentially expressed genes based on the Gene Expression Omnibus database and further gene enrichment analysis indicates that the tyrosine kinase-binding protein TYROBP is a potential prognostic marker for multiple myeloma. Multiple myeloma is a refractory hematological cancer characterized by the malignant proliferation of plasma cells. The tyrosine kinase-binding protein TYROBP mediates...

Double-hit newly diagnosed multiple myeloma patients with minimal residual disease positivity have a poor prognosis compared to patients with minimal residual disease negativity, according to the results of a recent cohort study. Autologous stem cell transplantation (ASCT) is one of the novel therapeutic approaches that are beneficial for newly diagnosed multiple myeloma (NDMM) patients. The...

A random forest radiomics model achieved satisfactory diagnostic performance, and models based on joint CET1 and T2-weighted imaging demonstrated better performance than single-sequence models in differentiating spinal multiple myeloma from metastases.  Spinal metastases and spinal multiple myeloma have similar radiographic characteristics, making accurate differentiation a necessity for precision therapy.  This retrospective study established and assessed...

A new cohort study reports that soluble B-cell maturation antigen is present in the lacrimal fluid of multiple myeloma patients, with evidence of pinocytosis as the underlying mechanism contributing to the development of keratopathy in these patients. Belantamab is an anti-B-cell maturation antigen (anti-BCMA) antibody–drug conjugate approved for the pharmacological treatment of refractory multiple myeloma....

A retrospective analysis finds high-risk fluorescent in situ hybridization markers useful for stratifying real-world survival outcomes in newly diagnosed multiple myeloma patients. Interphase fluorescent in situ hybridization (iFISH) remains the standard of care for assessing prognosis in patients with newly diagnosed multiple myeloma (NDMM). There is, however, limited data regarding iFISH-based real-world survival outcomes. In...